Table 1 A list of different SARS-CoV-2 variants that occurred globally
From: SARS-CoV-2 infection: a global outbreak and its implication on public health
COVID variant | Substitutions in spike protein | Origin | Characteristics | References |
|---|---|---|---|---|
B.1.1.7 | Δ69/70, Δ144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H | UK | Approx. 50% transmission No impact with monoclonal antibody treatment | Wang et al. (2021) |
B.1.351 | D80A, D215G, Δ241/242/243, K417N, E484K, N501Y, D614G, A701V | South Africa | Approx. 50% transmission Decrease with combination of bamlanivimab and etesevimab and monoclonal antibody treatment | |
B.1.427 | L452R, D614G | USA | Approx. 20% transmission Less chance of decrease with combination of bamlanivimab and etesevimab and monoclonal antibody treatment | Zhou et al. (2021) |
B.1.429 | S13I, W152C, L452R, D614G | USA | Approx. 20% transmission Less chance of decrease with combination of bamlanivimab and etesevimab and monoclonal antibody treatment | Zhou et al. (2021) |
P.1 | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I | Brazil and Japan | Decrease with combination of bamlanivimab and etesevimab and monoclonal antibody treatment | Zhou et al. (2021) |
B.1.526 | T95I, D253G, D614G | USA | Decrease with combination of bamlanivimab and etesevimab and monoclonal antibody treatment | Annavajhala et al. (2021) |
B.1.526.1 | Spike: D80G, Δ144, F157S, L452R, D614G, (T791I*), (T859N*), D950H | USA | Reduction in neutralization by some EUA monoclonal antibody treatments | Annavajhala et al. (2021) |
B.1.525 | Spike: A67V, Δ69/70, Δ144, E484K, D614G, Q677H, F888L | UK/Nigeria | EUA monoclonal antibody treatments | Zhou et al. (2021) |
P.2 | Spike: E484K, (F565L*), D614G, V1176F | Brazil | EUA monoclonal antibody treatments | Zhou et al. (2021) |
B.1.617 | Spike:Â L452R, E484Q, D614G | India | Potential reduction in neutralization by some EUA monoclonal antibody treatments | Yadav et al. (2021) |
B.1.617.1 | Spike:Â (T95I), G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H | India | EUA monoclonal antibody treatments | Yadav et al. (2021) |
B.1.617.2 | Spike: T19R, (G142D), Δ156, Δ157, R158G, L452R, T478K, D614G, P681R, D950N | India | EUA monoclonal antibody treatments | Yadav et al. (2021) |
B.1.617.3 | Spike:Â T19R, G142D, L452R, E484Q, D614G, P681R, D950N | India | EUA monoclonal antibody treatments | Yadav et al. (2021) |